Literature DB >> 3486601

Primary prevention and coronary heart disease: the economic benefits of lowering serum cholesterol.

G Oster, A M Epstein.   

Abstract

We examined the expected economic benefits of cholesterol lowering for adult men with significant elevations of total serum cholesterol (above 260 mg/dl), incorporating estimates of direct benefits from anticipated reductions in lifetime expenditures for medical care, and estimates of indirect benefits related to extension of work-life secondary to reductions in morbidity and premature mortality. Our findings yield discounted lifetime direct benefits of a 15 per cent reduction in total serum cholesterol of $3 to $208 per person, and discounted lifetime indirect benefits of $1 to $8,946. Benefits increase with an individual's initial cholesterol level and decrease with the age at which an intervention is initiated. Economic benefits increase approximately twofold in the presence of other coronary risk factors, such as cigarette smoking and hypertension. Results suggest that cholesterol-lowering interventions, no matter what their cost, are unlikely to result in substantial direct savings to the health care system. However, the indirect benefits of intervention are quite high for young and middle-aged adults, as well as for those with severe elevations of cholesterol or with additional coronary risk factors.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3486601      PMCID: PMC1646773          DOI: 10.2105/ajph.76.6.647

Source DB:  PubMed          Journal:  Am J Public Health        ISSN: 0090-0036            Impact factor:   9.308


  14 in total

1.  Fees: where they stand in 11 specialties.

Authors:  M Kirchner
Journal:  Med Econ       Date:  1980-10-13

2.  Fee increases: restraint takes over.

Authors:  M Kirchner
Journal:  Med Econ       Date:  1982-10-11

3.  Poverty and disease.

Authors:  C E A WINSLOW
Journal:  Am J Public Health Nations Health       Date:  1948-01

Review 4.  George Lyman Duff Memorial Lecture. Lifestyles, major risk factors, proof and public policy.

Authors:  J Stamler
Journal:  Circulation       Date:  1978-07       Impact factor: 29.690

5.  The role of cholesterol in coronary atherogenesis.

Authors:  W B Dannel
Journal:  Med Clin North Am       Date:  1974-03       Impact factor: 5.456

6.  Clofibrate in ischemic heart disease.

Authors:  W T Friedewald; M Halperin
Journal:  Ann Intern Med       Date:  1972-05       Impact factor: 25.391

7.  Cardiac-catheterization and cardiac-surgical facilities: use, trends, and future requirements.

Authors:  R H Kennedy; M A Kennedy; R L Frye; E R Giuliani; D C McGoon; J R Pluth; H C Smith; D G Ritter; F T Nobrega; L T Kurland
Journal:  N Engl J Med       Date:  1982-10-14       Impact factor: 91.245

8.  The decline in cardiovascular disease mortality.

Authors:  R I Levy
Journal:  Annu Rev Public Health       Date:  1981       Impact factor: 21.981

9.  Benefit and cost analysis in geriatric care. Turning age discrimination into health policy.

Authors:  J Avorn
Journal:  N Engl J Med       Date:  1984-05-17       Impact factor: 91.245

10.  Prognosis after initial myocardial infarction: the Framingham study.

Authors:  W B Kannel; P Sorlie; P M McNamara
Journal:  Am J Cardiol       Date:  1979-07       Impact factor: 2.778

View more
  20 in total

Review 1.  Cost-effectiveness of drug therapy for hypercholesterolaemia: a review of the literature.

Authors:  D Thompson; G Oster
Journal:  Pharmacoeconomics       Date:  1992-07       Impact factor: 4.981

Review 2.  Costs of illness in cost-effectiveness analysis. A review of the methodology.

Authors:  T A Hodgson
Journal:  Pharmacoeconomics       Date:  1994-12       Impact factor: 4.981

3.  One state's approach to the regulation of cholesterol screening.

Authors:  J M DeBoy
Journal:  Public Health Rep       Date:  1990 Nov-Dec       Impact factor: 2.792

4.  Cost effectiveness of incremental programmes for lowering serum cholesterol concentration: is individual intervention worth while?

Authors:  I S Kristiansen; A E Eggen; D S Thelle
Journal:  BMJ       Date:  1991-05-11

5.  The effects of workplace health promotion on absenteeism and employment costs in a large industrial population.

Authors:  R L Bertera
Journal:  Am J Public Health       Date:  1990-09       Impact factor: 9.308

6.  Cost effectiveness of adding ezetimibe to atorvastatin therapy in patients not at cholesterol treatment goal in Canada.

Authors:  Michele Kohli; Cheryl Attard; Annette Lam; Daniel Huse; John Cook; Chantal Bourgault; Evo Alemao; Donald Yin; Michael Marentette
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 7.  Simvastatin: a pharmacoeconomic evaluation of its cost-effectiveness in hypercholesterolaemia and prevention of coronary heart disease.

Authors:  P Chrisp; N J Lewis; R J Milne
Journal:  Pharmacoeconomics       Date:  1992-02       Impact factor: 4.981

8.  A new method of estimating cost effectiveness of cholesterol reduction therapy for prevention of heart disease.

Authors:  S Kinlay; D O'Connell; D Evans; J Halliday
Journal:  Pharmacoeconomics       Date:  1994-03       Impact factor: 4.981

9.  Attitudes and practices of primary care physicians in the management of elevated serum cholesterol levels.

Authors:  N R Langner; P D Hasselback; G C Dunkley; S J Corber
Journal:  CMAJ       Date:  1989-07-01       Impact factor: 8.262

10.  A cost-effectiveness analysis of exercise as a health promotion activity.

Authors:  E I Hatziandreu; J P Koplan; M C Weinstein; C J Caspersen; K E Warner
Journal:  Am J Public Health       Date:  1988-11       Impact factor: 9.308

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.